BIIB vs NTNX · P/E 21, rev $9.89B vs P/E 108, rev $2.54B
Biogen Inc (BIIB) versus Nutanix Inc (NTNX) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Nutanix Inc (NTNX) is a software - infrastructure company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported NTNX revenue for 2025-07-31 was $2.54B. Net income was $188.4M. Revenue was up 18.1% from 2024-07-31 to 2025-07-31. NTNX currently screens at market cap $18.74B and trailing P/E 107.6.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. NTNX currently screens at market cap $18.74B and trailing P/E 107.6.
Not investment advice. Open the BIIB and NTNX stock pages for the full models.
Not investment advice.